Tolga Tanguler - Feb 27, 2025 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler
Stock symbol
ALNY
Transactions as of
Feb 27, 2025
Transactions value $
-$123,983
Form type
4
Date filed
3/3/2025, 04:31 PM
Previous filing
Nov 27, 2024
Next filing
Mar 5, 2025

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Restricted Stock Units Options Exercise $0 -1.67K -50.02% $0.00 1.67K Feb 27, 2025 Common Stock 1.67K Direct F10, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10 These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.
F11 On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.